Company profile: Foundation Medicine
1.1 - Company Overview
Company description
- Provider of molecular information and clinical diagnostic tests for personalized cancer care, including FoundationOne CDx tissue-based comprehensive genomic profiling, FoundationOne Liquid CDx blood-based ctDNA profiling, FoundationOne Heme for hematologic malignancies, FoundationOne RNA fusion detection in solid tumors, the FoundationCore cancer genomic database, and Molecular Tumor Boards.
Products and services
- FoundationOne Liquid CDx: Blood-based test identifying genomic alterations in circulating tumor DNA, delivering insight into cancer treatment options and informing therapy decisions
- FoundationOne CDx: Tissue-based comprehensive genomic profiling test that detects genomic alterations and gene fusions in cancer, aiding therapy selection and guiding treatment decisions
- FoundationOne RNA: RNA-sequencing test that detects fusions across 318 genes in solid tumors, complementing DNA-based fusion detection to broaden fusion discovery for interpretation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Foundation Medicine
Immago
HQ: United Kingdom
Website
- Description: Provider of antibody-modulating enzyme approaches to enhance antibody-based cancer therapies, applying 'receptor refocusing' to modulate the endogenous antibody repertoire and enhance immune-mediated killing of cancer cells.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immago company profile →
Ambit Biosciences
HQ: United States
Website
- Description: Provider of small molecule kinase inhibitor discovery and development for cancer, autoimmune, and inflammatory diseases, including quizartinib (AC220), a potent, selective FLT3 inhibitor for AML, AC410 (JAK2 inhibitor), and AC708 (CSF1R inhibitor), supported by the KinomeScan platform for screening kinase inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ambit Biosciences company profile →
AVEO Oncology
HQ: United States
Website
- Description: Provider of targeted cancer therapeutics and oncology development platforms. Products include FOTIVDA (tivozanib), an oral VEGFR TKI approved for relapsed/refractory advanced RCC. Pipeline includes ficlatuzumab (anti-HGF) for HNSCC, AV-380 (anti-GDF15) for cancer cachexia, and AV-203, a HER3 inhibitory antibody. Offers an integrated cancer biology and Human Response platform for efficient discovery and development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AVEO Oncology company profile →
GenomeDx
HQ: Canada
Website
- Description: Provider of genomic-based laboratory tests for personalized medicine in cancer care, including the Decipher Prostate Cancer Classifier for independent assessment of tumor aggressiveness, the Decipher GRID genomic expression database in urologic cancer, and genomic testing and a development pipeline focused on creating genomic tests for urologic cancers to aid personalized treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenomeDx company profile →
Profound Medical
HQ: Canada
Website
- Description: Provider of medical device solutions for MRI-guided ablation in prostate care, offering TULSA-PRO, a transurethral ultrasound ablation system under MRI guidance; Sonalleve, a HIFU therapy platform for non-invasive treatment of uterine fibroids and palliative bone metastases pain; and PRO-Talk, an educational platform with learning resources for physicians.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Profound Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Foundation Medicine
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Foundation Medicine
2.2 - Growth funds investing in similar companies to Foundation Medicine
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Foundation Medicine
4.2 - Public trading comparable groups for Foundation Medicine
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →